% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • mastino88 mastino88 Jan 29, 2001 5:18 PM Flag

    Exelixis Announces Key Additions to Dru


    Exelixis Announces Key Additions to Drug Discovery Team
    SOUTH SAN FRANCISCO, Calif., Jan 29, 2001 /PRNewswire via COMTEX/ -- Exelixis,
    Inc. (Nasdaq: EXEL) today announced the addition of four key members to its
    scientific staff: Peter Lamb, Ph.D., as Senior Director of Molecular
    Pharmacology and Structural Biology; Kirk McMillan, Ph.D., Director of New Lead
    Discovery; John Nuss, Ph.D., Senior Director of Chemistry; and Yifan Zhai, M.D.,
    Ph.D., Director of Pharmacology.

    "I am pleased to welcome Peter, Kirk, John, and Yifan to Exelixis and am
    confident that their collective experience and expertise will further enhance
    our rapidly expanding drug discovery program," stated George A. Scangos, Ph.D.,
    president and chief executive officer of Exelixis, Inc. "The addition of these
    high quality individuals to our talented team, in combination with our
    leadership position in genetics, biological validation, and informatics,
    strengthens an already powerful drug discovery platform, and accelerates the
    pace of our drug discovery pipeline."

    Peter Lamb, Ph.D., brings significant knowledge and proficiency in the
    development of cell based assays for lead discovery and characterization to
    Exelixis, Inc. Dr. Lamb most recently served as Director of Transcription
    Research at Ligand Pharmaceuticals, where he was responsible for the development
    and implementation of assays for lead characterization, as well as the
    determination of the mechanism of action of selected compounds.

    Kirk McMillan, Ph.D., joins Exelixis from Pharmacopeia, Inc., where he held
    positions of increasing responsibility, most recently serving as Assistant
    Director of Drug Discovery. At Pharmacopeia, Dr. McMillan's efforts were
    concentrated toward assay development, high-throughput screening, and lead
    optimization, with the goal of identifying compounds for late preclinical and
    clinical evaluation. Prior to Pharmacopeia, Dr. McMillan worked extensively with
    human nitric oxide synthase at the University of Texas Health Science Center.

    John Nuss, Ph.D., brings considerable experience and expertise in small molecule
    drug discovery and combinatorial chemistry to Exelixis, Inc. Dr. Nuss most
    recently served as Director of Organic and Medicinal Chemistry for Chiron
    Corporation, where he directed discovery efforts in the areas of oncology and

    This topic is deleted.
6.34+0.04(+0.63%)May 27 4:00 PMEDT